AstraZeneca shares technical analysis: Downward move persists as seller pressure dominates

Traders Union
All News
Stocks
Astrazeneca slides 1% to GBX11,906 today

Highlights

AstraZeneca invested $1 billion in a new R&D facility in Massachusetts, expanding research operations in the Kendall Square life sciences hub.
The company advanced its clinical pipeline with pediatric Nexium Phase III progress, updated rare disease results, new oncology partnerships, and reaffirmed full-year revenue guidance.
Shares of AstraZeneca fell 1% to GBX11,906 and remain under strong selling pressure, with technical indicators signaling a high probability of continued downside in the GBX11,594 to GBX12,097 range.

Operational expansion and pipeline progress drive long-term growth narrative

AstraZeneca opened a new US$1 billion R&D facility in Massachusetts, significantly expanding its research capabilities in the Kendall Square life sciences hub, according to Healthcaremea. This completed investment broadens the company’s operational presence and signals an ongoing commitment to long-term pipeline innovation. Additional developments included progress in the pediatric Nexium Phase III study, updated rare disease trial results, new partnerships in precision oncology, and a reaffirmed full-year outlook supported by revenue growth and earnings in its core therapeutic areas.

Layered resistance and oversold signals amid sellers’ dominance

On the technical front, AZN remains below the SMA-20 at GBX12,068 and SMA-50 at GBX12,045 on the hourly chart, with the longer-term SMA-200 positioned higher at GBX13,510 on the daily, creating a series of layered resistance overhead. The Ichimoku Kijun lines up as the next hurdle at GBX12,096. MACD and ADX are both neutral, offering no momentum signal, while RSI stands at 39.14, pointing to oversold territory. Both Stochastic RSI and CCI reinforce the oversold conditions, with Bull/Bear Power and the Awesome Oscillator aligning on the sell side, reflecting heavy dominance by sellers.

Sideline trading expected as reversal odds remain low

Over the next several days, the price is likely to consolidate within a range of GBX11,594 to GBX12,097, reflecting typical volatility around current levels. Probability modeling indicates just a 26% chance of a bounce, with a 74% likelihood of further downside and a lower probability of reversal. The baseline scenario points to sideways to slightly negative drift near support, with a bullish reversal dependent on a break above the Kijun at GBX12,096 and a bearish case sharpening on a decisive move below GBX11,594.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca’s technical setup as vulnerable, with the stock trapped below key moving averages and momentum indicators skewed to the downside. Fundamentals show some support from major R&D investments and sustained revenues, but mixed clinical data and heavy selling pressure limit near-term upside. Base case remains sideways to mildly negative as long as GBX12,096 holds as resistance. "Until AZN reclaims the Kijun and clears layered resistance, I remain cautious on any bullish scenario here."

Earlier, analysts noted that AstraZeneca shares remained under sustained technical pressure, with downside risks prevailing despite ongoing pipeline initiatives and expansion efforts. The latest data confirm that bearish momentum persists and highlight GBX11,594 as a crucial support level, making a decisive move below this threshold a key trigger for further downside risk.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.